Plasma adiponectin concentration in patients after successful kidney transplantaion - A single-center, observational study

Clinical Nephrology

Volumn 67, Issue 6, 2007, Pages 381-390

  Adamczak, M ^a   Szotowska, M ^a   Chudek, J ^a   Karkoszka, H ^a   Cierpka, L ^a   Wiecek A ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adiponectin; Estimated GFR; Kidney transplantation

Indexed keywords

ADIPONECTIN; AZATHIOPRINE; CYCLOSPORIN; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEMODIALYSIS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SURVIVAL TIME;

EID: 34250155688     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp67381     Document Type: Article

References (35)

1. Adamczak M, Czerwienska B, Chudek J, Wieçek A. Renal extraction of circulating adiponectin in patients with renovascular hypertension. Acta Physiol Hung. 2007; 94: 143-148.
2. Adamczak M, Rzepka E, Chudek J, Wieçek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxf). 2005; 62: 114-118.
3. Báyes B, Lauzurica R, Granada ML, Serra A, Bonet J, Fontseré N, Salinas I, Romero R. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation. 2004; 78: 26-30.
4. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D, MMKD Study Gro up. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005; 16: 1091-1098.
5. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998; 47: 1643-1649.
6. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, Matsuzawa Y, Cieroka L, Kokot F, Wieçek A. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc. 2003; 35: 2186-2189.
7. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, Berria R, Belfort R, DeFronzo RA, Mandarino LJ, Ravussin E. Adiponectin receptor gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetology. 2004; 47: 816-820.
8. Daimon M, Oizumi T, Sailoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M, Kato T, Funagata study. Decreased serum levels of adiponectin is a risk factor for the progression to Type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care. 2003; 26: 2015-2020.
9. González-Posada JP, Hernández D, Genís BB, Perez JG, Sanchez MR. Impact of diabetes mellitus on kidney transplant recipients in Spain. Nephrol Dial Transplant. 2004; 19: iii57-iii61.
10. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant. 2005; 20: 129-134.
11. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T. Effects of pioglitasone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with Type 2 diabetes. Metab Clin Exp. 2002; 51: 314-317.
12. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentration of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20: 1595-1599.
13. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003; 42: 76-82.
14. Ignacy W, Chudek J, Adamczak M, Funahashi T, Matsuzawa Y, Kokot F, Wieçek A. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease - a follow-up study. Nephron Clin Pract. 2005; 101: c18-c24.
15. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004; 109: 2046-2049.
16. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y, Osaka CAD Study Group. Association of hypoadiponectinemia with coronary artery disease in men. Atterioscler Thromb Vasc Biol. 2003; 23: 85-89.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 16: 461-470.
18. Maeda K, Okubo K, Funahashi TS, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose-specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun. 1996; 221: 286-289.
19. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin in essential hypertension. J Nephrol. 2002; 15: 507-511.
20. Malyszko J, Malyszko JS, Brzosko S, Wolczynski S, Mysliwiec M. Markers of endothelial cell activation/injury: CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients. Am J Nephrol. 2005; 25: 203-210.
21. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits-Filho R, Lonnqvist F, Schalling M, Heimburger O, Nordfors L. Reduced gene expression of adiponectin in fat fissue from patients with end-stage renal disease. Kidney Int. 2004; 66: 46-50.
22. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004; 315: 264-271.
23. Nowak L, Adamczak M, Wieçek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2005; 18: 1470-1475.
24. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100: 2473-2476.
25. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin and adipocyte-derived plasma protein inhibit endothelial NFκB signaling through a cAMP-dependent pathway. Circulation. 2000; 102: 1296-1301.
26. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103: 1057-1063.
27. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 14: 1730-1737.
28. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001; 15: 89-94.
29. Saraheimo M, Forsblom C, Fagerudd J, Teppo AM, Pettersson-Fernholm K, Frystyk J, Flyvbjerg A, Groop PH, Finn Diane study group. Serum adiponectin is increased in Type 1-diabetic patients with nephropathy. Diabetes Care. 2005; 28: 1410-1414.
30. Wzeçek A, Adamczak M, Chudek J. Adiponectin - an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007; 22: 981-988.
31. Yamauchi T, Kamon J, Ito Y. Cloning of adiponectin receptors that mediates antidiabetic metabolic effects. Nature. 2003; 423: 762-769.
32. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in Type 2 diabetic patients. Diabetes Care. 2002; 25: 376-380.
33. Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, Eyileten T, Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural A. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation. 2005; 80: 1660-1666.
34. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and Type 2-diabetic subjects. Diabetes. 2002; 51: 2968-2974.
35. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 134-141.